WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004031185) 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/031185    International Application No.:    PCT/GB2002/004491
Publication Date: 15.04.2004 International Filing Date: 04.10.2002
Chapter 2 Demand Filed:    04.03.2004    
IPC:
C07D 451/02 (2006.01)
Applicants: MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB)
Inventors: CURTIS, Neil, Roy; (GB).
HUSCROFT, Ian, Thomas; (GB).
KULAGOWSKI, Janusz, Jozef; (GB).
RAUBO, Piotr, Antoni; (GB)
Agent: HISCOCK, Ian, James; Merck & Co., Inc., European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).
MAN, J.; Merck & Co., Inc., European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB)
Priority Data:
Title (EN) 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS
(FR) DERIVES D'ETHER 8-AZABICYCLO[3.2.1]OCTANE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE RECEPTEUR DE NEUROKININE
Abstract: front page image
(EN)The present invention relates compounds of the formula (I) : wherein X represents hydrogen, C1-4alkyl optionally substituted by a hydroxy, methoxy or benzyloxy group, or CO2(C1-2alkyl); Z is -CR9R10CH2- or -CH2CR9R10-; and R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.
(FR)L'invention se rapporte à des composés de formule (I): dans laquelle X représente hydrogène, alkyle C1-4 éventuellement substitué par un groupe hydroxy, méthoxy ou benzyloxy, ou CO2(C1-2alkyle); Z représente -CR9R10CH2- ou -CH2CR9R10-; et R1, R2, R3, R4, R5 et R6 sont tels que définis dans la description. Les composés sont particulièrement utiles dans le traitement ou la prévention de la dépression, l'anxiété, la douleur, des inflammations, des migraines, des vomissements ou des algies post-zostériennes.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)